Has Jeffrey Mullen, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,053 in general payments to Jeffrey Mullen, MD across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Mullen, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Mullen, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Mullen, MD

Neuromuscular Medicine · Orange, CANPI 1447614276

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,491 of the $13,053 with a category attached, or 72.7%. 13 manufacturers reported payments, led by Argenx US, Inc. at 45.6% of the total. 2025 is the largest year on record at $12,725, more than ten times the $238 reported in 2021.

$13,053in general payments, 2019–2025

Across 46 payments — averaging $283.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$6K
Sanofi$3K
Genentech USA, Inc.$2K
Novartis$1K
Catalyst Pharmaceuticals, Inc.$164
Globus Medical$95
plus $273 from 7 others

$155,448in research payments, 2019–2025

Across 21 payments — averaging $7402.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi US Services Inc.$83K
CSL Behring$46K
Genentech, Inc.$26K

What the payments were for

Consulting fees$9,49173%
Travel & lodging$1,97815%
Food & beverage$1,55212%
Education$330%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	13	$5,951
Sanofi	2	$3,351
Genentech USA, Inc.	1	$1,920
Novartis	18	$1,299
Catalyst Pharmaceuticals, Inc.	2	$164
Globus Medical	1	$95
Sarepta Therapeutics, Inc.	1	$83
Tanabe Pharma America, Inc.	2	$55
Octapharma USA, Inc.	1	$37
UCB, Inc.	2	$33
Johnson & Johnson	1	$32
AstraZeneca	1	$22
CSL Behring	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,053 in reported general payments places this provider in the 70th percentile of 44 neuromuscular medicine providers in California.

See all neuromuscular medicine providers in California →

Medicare billing

Part B allowed, 2024

$80,630

Medicare patients

304

Services billed

618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Radicava OrsEdaravone	48	$664,784
Gamunex-CImmune Globul G/Gly/Iga Avg 46	35	$527,331
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50	34	$395,166
NuedextaDextromethorphan Hbr/Quinidine	16	$23,348
Emgality PenGalcanezumab-Gnlm	18	$13,997
Lacosamide	17	$5,632
Riluzole	52	$3,576
Gabapentin	116	$2,210
Scopolamine	13	$1,203
Memantine Hcl	32	$1,082
MethotrexateMethotrexate Sodium	35	$952
Pregabalin	17	$929
Glycopyrrolate	20	$850
Levetiracetam	30	$725
Duloxetine Hcl	17	$566

Paid to pharmacies, not to this prescriber.

Other neuromuscular medicine in Orange

Ali HabibOrange$445K
Tahseen MozaffarOrange$428K
Namita GoyalOrange$174K
Jay HanOrange$126K
Khalid AlrasheedOrange$75K
Jonathan CauchiOrange$895
Mona Rezaei MirghaedOrange$673
Samir MacwanRancho Mirage$983K
Jeffrey RosenfeldFresno$361K
John DayStanford$294K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →